These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 23032071)

  • 1. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
    Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
    Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
    Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
    McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
    Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
    Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
    Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues.
    Ray LA; Courtney KE; Hutchison KE; Mackillop J; Galvan A; Ghahremani DG
    Alcohol Clin Exp Res; 2014 Jan; 38(1):78-89. PubMed ID: 23876228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
    Schacht JP; Voronin KE; Randall PK; Anton RF
    Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
    Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
    Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
    Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
    Kranzler HR; Armeli S; Covault J; Tennen H
    Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects.
    Bach P; Vollsta Dt-Klein S; Kirsch M; Hoffmann S; Jorde A; Frank J; Charlet K; Beck A; Heinz A; Walter H; Sommer WH; Spanagel R; Rietschel M; Kiefer F
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1128-35. PubMed ID: 25937240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
    Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
    Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
    Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
    Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.